Connor Clark & Lunn Investment Management Ltd. Invests $69,000 in uniQure (NASDAQ:QURE)

Connor Clark & Lunn Investment Management Ltd. bought a new stake in uniQure (NASDAQ:QURE) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,050 shares of the biotechnology company’s stock, valued at approximately $69,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. abrdn plc raised its stake in shares of uniQure by 381.7% in the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after buying an additional 1,528,581 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in uniQure in the second quarter valued at about $815,000. Vanguard Group Inc. raised its position in uniQure by 11.4% in the first quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after purchasing an additional 109,740 shares in the last quarter. Privium Fund Management B.V. lifted its stake in uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after purchasing an additional 104,500 shares during the period. Finally, Algert Global LLC acquired a new stake in uniQure during the second quarter valued at approximately $176,000. 78.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating and issued a $28.00 target price on shares of uniQure in a report on Wednesday, November 6th. StockNews.com raised uniQure to a “sell” rating in a report on Thursday, October 17th. Raymond James restated an “outperform” rating and issued a $20.00 target price on shares of uniQure in a research note on Thursday, October 10th. Royal Bank of Canada dropped their target price on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Finally, The Goldman Sachs Group reduced their price target on shares of uniQure from $10.00 to $9.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $17.00.

uniQure Stock Performance

uniQure stock opened at $7.13 on Tuesday. The stock has a 50-day simple moving average of $6.02 and a 200 day simple moving average of $6.01. The stock has a market capitalization of $347.52 million, a price-to-earnings ratio of -1.44 and a beta of 0.90. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92. uniQure has a 12-month low of $3.73 and a 12-month high of $11.35.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.21. The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, research analysts anticipate that uniQure will post -3.81 earnings per share for the current fiscal year.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.